ImmunityBio (IBRX) Other Accumulated Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Other Accumulated Expenses data on file, last reported at $2.4 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 7.58% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 7.58% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, up 192.67% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $2.4 million, down from $3.1 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for IBRX reached as high as $3.1 million in Q4 2025 and fell as low as $556000.0 in Q1 2024.
• Historically, Other Accumulated Expenses has averaged $1.6 million across 5 years, with a median of $1.5 million in 2022.
• Across the five-year window, Other Accumulated Expenses slumped 65.82% in 2023 and soared 376.8% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.6 million in 2022, then tumbled by 56.02% to $716000.0 in 2023, then soared by 46.65% to $1.0 million in 2024, then soared by 192.67% to $3.1 million in 2025, then retreated by 20.27% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $2.4 million in Q1 2026, $3.1 million in Q4 2025, and $2.1 million in Q3 2025.